Sign In
Buy TNXP
$12.20
+0.190 (+1.58%)
At Close: Jun 22, 2026
Tonix Pharmaceuticals (NASDAQ:TNXP) versus Silence Therapeutics (NASDAQ:SLN) Critical Survey
01:40am, Friday, 31'st Oct 2025
Silence Therapeutics (NASDAQ: SLN - Get Free Report) and Tonix Pharmaceuticals (NASDAQ: TNXP - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two
Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025
07:00am, Tuesday, 28'th Oct 2025
CHATHAM, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biopharmaceutical company announce
Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Treatment was well tolerated with minimal effects on weight or blood pressure and di
FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix's investigational intranasal potentiated oxytocin products in patients with Arginine-Vasopressin Deficien
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence
07:00am, Tuesday, 21'st Oct 2025
CHATHAM, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated, commercial biotechnology company, announced
Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025
07:00am, Friday, 17'th Oct 2025
TNX-801 is a live virus vaccine investigational candidate, designed to provide durable protection against mpox and smallpox
CHATHAM, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated biotechnology company with marketed products
Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025
07:00am, Thursday, 09'th Oct 2025
CHATHAM, N.J., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biotechnology company with marketed products
Tonix Pharmaceuticals appoints industry veteran Ganesh Kamath as Head of Market Access
09:09am, Tuesday, 30'th Sep 2025
Tonix Pharmaceuticals (NASDAQ:TNXP) announced the appointment of Ganesh Kamath as its head of market access, effective September 29, 2025. The biotechnology company said Kamath brings more than 2
Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access
08:30am, Tuesday, 30'th Sep 2025
Mr. Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix On August 15, 2025, the U.S. Food and Drug Administration approved Tonmya™ (cyclobenzapr
Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND
Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder
08:00am, Thursday, 18'th Sep 2025
Tonix anticipates filing the IND application in the fourth quarter of 2025 TNX-102 SL is a potential first-in-class treatment for targeting the disturbed sleep associated with depression TNX-102 SL is
Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
07:00am, Wednesday, 17'th Sep 2025
Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: 1)
Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025
07:00am, Monday, 08'th Sep 2025
Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new FDA approved treatment for fibromyalgia in over 15 years Two pivotal Phase 3 studies demonstrated T
Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025
07:00am, Thursday, 28'th Aug 2025
CHATHAM, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biotechnology company with marketed products
